Eli Lilly

News

Weight-loss drugs ‘will be a $60bn market in 10 years’

Frantic demand for drugs to treat obesity from Novo Nordisk, Eli Lilly, and others could support a global market worth an eye-watering $60 billion within the next decade,

News

ASCO: Novartis touts Kisqali adjuvant breast cancer data

Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte

News

CMS update on Alzheimer's coverage raises questions

The Centres for Medicare and Medicaid Services (CMS) has formally announced its intention to allow coverage of new amyloid-targeting drugs for Alzheimer’s disease if they

News

Novo Nordisk says oral Wegovy hits weight loss goal

Novo Nordisk has struck back in its growing rivalry with Eli Lilly in the obesity market, with data showing a higher-dose version of its oral version of weight loss drug W

News

Boehringer shows its hand in obesity

Boehringer Ingelheim and partner Zealand Pharma have reported new clinical data in obesity for their dual glucagon/GLP1 agonist BI 456906, setting up a possible challenge

News

Farxiga back on level pegging in heart failure

The FDA has approved AstraZeneca’s SGLT2 inhibitor Farxiga as a treatment candidate for all patients with heart failure, putting the drug back in contention with rival Jar

Weight-loss drugs ‘will be a $60bn market in 10 years’

ASCO: Novartis touts Kisqali adjuvant breast cancer data

CMS update on Alzheimer's coverage raises questions

Novo Nordisk says oral Wegovy hits weight loss goal

Boehringer shows its hand in obesity

Farxiga back on level pegging in heart failure

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Eli Lilly

Editor's Picks